Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00100698
Status:
COMPLETED
Last Update Posted:
2010-07-27
First Post:
2005-01-04
Brief Title:
Physiologic Growth Hormone Effects in HIV Lipodystrophy
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Study Overview
Official Title:
Physiologic Growth Hormone Effects in HIV Lipodystrophy
Status:
COMPLETED
Status Verified Date:
2010-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will investigate long-term low-dose growth hormone administration in HIV-infected patients with reduced growth hormone GH secretion and increased visceral adiposity We hypothesize that low-dose growth hormone will reduce visceral fat Secondary endpoints will include measures of insulin-like growth factor-1 IGF-1 glucose homeostasis lipids blood pressurebone density cardiovascular risk and safety parameters
Detailed Description:
This study will investigate long-term low-dose growth hormone administration in HIV-infected patients with reduced growth hormone GH secretion and increased visceral adiposity We hypothesize that low-dose growth hormone will reduce visceral fat preferentially over subcutaneous fat and increase lean body mass Secondary endpoints will include measures of IGF-1 glucose homeostasis lipids blood pressurebone density cardiovascular risk and safety parameters Dosing of growth hormone will be based on patients IGF-1 levels and will not exceed 6mcgkgday
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01DK063639 | NIH | None | httpsreporternihgovquickSearchR01DK063639 |